Mantle Cell Lymphoma (MCL) Trials
Explore how clinical research is advancing treatment and discover studies that may be a match for your diagnosis and treatment history.
What are Mantle Cell Lymphoma trials?
MCL trials are research studies evaluating new treatments for people living with mantle cell lymphoma. Current studies investigate BTK inhibitors, CAR-T cell therapy, bispecific antibodies, targeted therapies, antibody-drug conjugates, and innovative treatment combinations.
Some trials focus on newly diagnosed disease, while others are designed for relapsed or refractory MCL or patients with high-risk features such as TP53 abnormalities. Because eligibility often depends on prior treatments, disease subtype, biomarkers, and overall health, finding the right clinical trial can be challenging.
CancerBot helps patients and clinicians find mantle cell lymphoma clinical trials they are actually eligible for using AI-powered matching. Instead of manually reviewing hundreds of studies, CancerBot analyzes trial eligibility criteria and provides personalized matches in minutes.
Understanding Mantle Cell Lymphoma (MCL)
Mantle cell lymphoma is a rare type of B-cell lymphoma that develops from lymphocytes in the mantle zone of lymph nodes. It most commonly affects lymph nodes but may also involve the bone marrow, spleen, blood, or gastrointestinal tract.
MCL can behave differently between individuals. Some people have indolent (slow-growing) disease that may initially require observation, while others develop aggressive disease that requires prompt treatment.
Types and risk categories in MCL
CL may behave differently depending on disease biology and molecular features.
Indolent MCL: Slow-growing disease that may initially be monitored without immediate treatment.
Aggressive MCL: Disease requiring prompt treatment because of symptoms or rapid progression.
Relapsed/refractory MCL: Disease returning after treatment or resistant to therapy
High-risk MCL: Associated with TP53 abnormalities, blastoid or pleomorphic morphology, high Ki-67, or other adverse biological features.
Understanding disease biology is critical for selecting appropriate therapies and clinical trial opportunities.
How diagnosis works
Diagnosis typically involves:
Lymph Node or Tissue Biopsy: Confirms the diagnosis by identifying lymphoma cells and examining their microscopic appearance.
Immunohistochemistry (IHC): Detects proteins expressed by lymphoma cells, including Cyclin D1, SOX11, CD5, CD20, and other markers that help distinguish MCL from other lymphomas.
Flow Cytometry: Analyzes proteins on the surface of blood cells to identify abnormal B lymphocytes characteristic of MCL.
Blood Marrow Biopsy to determine whether lymphoma has spread to the bone marrow.
Imaging Studies (CT or PET scans) to evaluate enlarged lymph nodes, spleen, or organ involvement and to determine the extent (stage) of disease throughout the body.
Cytogenetic and Molecular Testing: Identifies genetic abnormalities such as the t(11;14) translocation, TP53 mutation, or del(17p), which may influence prognosis and treatment selection.
These findings help determine prognosis and guide treatment selection.
Common symptoms
Symptoms vary widely between individuals. Common signs may include:
Enlarged lymph nodes
Fatigue or weakness
Night sweats
Fever
Unexplained weight loss
Enlarged spleen
Abdominal discomfort or fullness
Gastrointestinal symptoms in some patients
Some people may not experience symptoms at all, which is why routine screening is so important.
Treatment options
Patients with indolent MCL may initially undergo active surveillance ("watch and wait"), whereas patients with aggressive MCL generally require immediate treatment.
Treatment depends on disease behavior, stage, biomarkers, previous therapies, and overall health.
Common treatment approaches include:
Chemoimmunotherapy
BTK inhibitors
Anti-CD20 monoclonal antibodies
Autologous stem cell transplantation (in selected patients)
CAR-T cell therapy
Bispecific antibodies
Maintenance therapy
Clinical trials may provide access to innovative therapies before they become widely available.
Mantle Cell Lymphoma clinical trials available now
Current MCL trials are evaluating:
Next-generation BTK inhibitors
Non-covalent BTK inhibitors
CAR-T cell therapies
Bispecific antibodies
Antibody-drug conjugates
Novel targeted combinations
Treatments for TP53-abnormal disease
Some studies focus on newly diagnosed patients, while others are designed for relapsed disease, BTK inhibitor–exposed patients, or individuals with high-risk molecular features.
Because eligibility criteria vary significantly between studies, precision matching improves access and reduces missed opportunities.
Blog
Related research and insights
Start your Al-powered clinical trial search
New treatment options could be just a click away. Start a chat with CancerBot matched with clinical trials tailored to you-quickly, easily, and at no cost.
Frequently asked questions
Everything else you need to know.
Who qualifies for Mantle Cell Lymphoma trials?
Eligibility depends on disease stage, prior treatments, biomarkers, performance status, organ function, and overall health. Each study has its own inclusion and exclusion criteria.
Are trials only for advanced or relapsed disease?
No. Some studies enroll newly diagnosed patients, while others focus on relapsed or refractory mantle cell lymphoma or high-risk disease.
Are BTK inhibitors and CAR-T therapies available through clinical trials?
Yes. Many current MCL trials evaluate next-generation BTK inhibitors, CAR-T therapy, bispecific antibodies, and targeted treatment combinations.
Does it cost money to join a clinical trial?
Investigational treatments and study-related procedures are generally covered by the trial sponsor. Standard care costs are handled according to usual medical billing practices.